28.75

1.45% 0.41

After Hours: 28.75

Assembly Biosciences Inc (ASMB)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Assembly Biosciences Inc stock is traded at $28.75, with a volume of 244.65K. It is up +1.45% in the last 24 hours and up +3.16% over the past month. Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

Previous Close:

$28.34

Open:

$28.33

24h Volume:

244.65K

Relative Volume:

2.04

Market Cap:

$456.91M

Revenue:

$71.10M

Net Income/Loss:

$-6.38M

P/E Ratio:

-23.94

EPS:

-1.2009

Net Cash Flow:

$-39.84M

1W Performance:

+8.41%

1M Performance:

+3.16%

6M Performance:

-22.69%

1Y Performance:

+112.65%

1-Day Range:

$27.41

$29.05

1-Week Range:

$25.76

$31.89

52-Week Range:

$13.70

$39.70

Assembly Biosciences Inc Stock (ASMB) Company Profile

Name

Assembly Biosciences Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

(833) 409-4583

Address

TWO TOWER PLACE, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

ASMB's Discussions on Twitter

Compare ASMB vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ASMB Assembly Biosciences Inc	28.75	450.40M	71.10M	-6.38M	-39.84M	-1.2009
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-25	Initiated	Citizens JMP	Mkt Outperform
Aug-18-25	Resumed	H.C. Wainwright	Buy
Mar-25-25	Initiated	Guggenheim	Buy
Sep-20-24	Upgrade	Jefferies	Hold → Buy
Sep-13-21	Initiated	H.C. Wainwright	Neutral
Sep-02-21	Downgrade	William Blair	Outperform → Mkt Perform
Mar-23-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Nov-06-20	Downgrade	Jefferies	Buy → Hold
Oct-19-20	Initiated	Truist	Buy
Oct-16-19	Initiated	Mizuho	Buy
Nov-19-18	Initiated	Leerink Partners	Outperform
Oct-08-18	Upgrade	B. Riley FBR	Neutral → Buy
Aug-08-18	Initiated	Robert W. Baird	Outperform
Apr-13-18	Downgrade	Chardan Capital Markets	Buy → Neutral
Jan-05-18	Initiated	B. Riley FBR, Inc.	Neutral
Nov-08-17	Initiated	Jefferies	Buy
May-30-17	Initiated	Chardan Capital Markets	Buy

View All

Assembly Biosciences Inc Stock (ASMB) Latest News

May 26, 2026

Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks

May 26, 2026

Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com Australia

May 26, 2026

Assembly Biosciences closes $115 million stock offering - Investing.com

May 26, 2026

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times

May 26, 2026

Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan

May 26, 2026

Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan

May 26, 2026

May 25, 2026

Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)BPI Bull Correction - Newser

May 25, 2026

May 23, 2026

Assembly Biosciences prices $100M equity offering - MSN

May 23, 2026

Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm

Assembly Biosciences Inc (ASMB)

Assembly Biosciences Inc Stock (ASMB) Company Profile

Compare ASMB vs VRTX, REGN, ARGX, ALNY, RVMD

Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades

Assembly Biosciences Inc Stock (ASMB) Latest News

Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks

Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com Australia

Assembly Biosciences closes $115 million stock offering - Investing.com

Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times

Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan

Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan

Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)BPI Bull Correction - Newser

Assembly Biosciences prices $100M equity offering - MSN

Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm

Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView

Assembly Biosciences (NASDAQ: ASMB) raises ~$93M; 3.36M shares, 415K pre-funded warrants - Stock Titan

Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus

Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus

Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan

Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK

Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart

Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria

Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com UK

Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa

Assembly Biosciences prices $100 million offering - The Pharma Letter

Assembly Biosciences Shares Up Amid Expansion of ABI-6250 Drug Development - Moomoo

Assembly Biosciences stock surges on PBC and PSC expansion plan By Investing.com - Investing.com Australia

Assembly Biosciences stock surges on PBC and PSC expansion plan - Investing.com

Assembly Biosciences Expands ABI-6250 Liver Disease Program - TipRanks

Assembly Biosciences Prices $100 Million Offering - Moomoo

Assembly Bio (NASDAQ: ASMB) plans Phase 2 ABI-6250 trials in HDV, PBC and PSC - Stock Titan

Assembly Biosciences Plans Phase 2 Study of ABI-6250 in Cholestatic Liver Diseases PBC and PSC to Begin in Q1 2027 - Quiver Quantitative

Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases - The Manila Times

Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - marketscreener.com

Biotech Assembly Bio prices $100M sale to fund viral, liver drug work - Stock Titan

Experimental liver drug ABI-6250 heads to Phase 2 tests in PBC and PSC - Stock Titan

Crude Oil Edges Higher; US Consumer Sentiment Falls In May - Sahm

Trading Systems Reacting to (ASMB) Volatility - Stock Traders Daily

Assembly Biosciences, Inc.Common Stock (ASMB) Stock Price, News, Quote & History - FinancialContent

Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference - Yahoo Finance

Assembly Biosciences Shares Caution As Healthcare Growth Expectations Fade - Kalkine Media

These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - simplywall.st

Assembly Biosciences to present HDV drug data at EASL congress - Investing.com

Assembly Biosciences to present HDV drug data at EASL congress By Investing.com - Investing.com Australia

Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 - The Manila Times

Assembly Biosciences to Present Topline Clinical Data on ABI-6250, a Novel Oral Hepatitis D Virus Entry Inhibitor, at EASL Congress 2026 - Quiver Quantitative

Oral hepatitis D entry inhibitor brings Phase 1a data to Barcelona - Stock Titan

MarketsMedicine Hat News - FinancialContent

Paradigm entities and Dr. Asefaw report holdings in Assembly Biosciences (ASMB) - Stock Titan

Analysts Have Lowered Expectations For Assembly Biosciences, Inc. (NASDAQ:ASMB) After Its Latest Results - simplywall.st

Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference - Weekly Voice

Biotech Assembly Bio to speak at BofA 2026 Global Health Care Conference - Stock Titan

We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely - Yahoo Finance

Guggenheim Maintains Assembly Biosciences(ASMB.US) With Buy Rating, Maintains Target Price $43 - Moomoo

Assembly Biosciences 1Q Loss/Shr 54c >ASMB - Moomoo

How Assembly Bio (ASMB) benefits from the shifts in its industry (-1.37%) 2026-05-08SuperTrend - Newser

Assembly Biosciences Inc Stock (ASMB) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to ASMB